These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 25795101)

  • 1. Lenvatinib: first global approval.
    Scott LJ
    Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
    Hegazi M; Azadi A; Jain D; Redman R; Perez CA
    Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Yeung KT; Cohen EE
    Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib: A Review in Refractory Thyroid Cancer.
    Frampton JE
    Target Oncol; 2016 Feb; 11(1):115-22. PubMed ID: 26867945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib approved for certain thyroid cancers.
    Cancer Discov; 2015 Apr; 5(4):338. PubMed ID: 25720434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
    Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
    Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib receives approval in DTC.
    J Nucl Med; 2015 Apr; 56(4):12N. PubMed ID: 25834176
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenvatinib improves survival in refractory thyroid cancer.
    Mayor S
    Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
    Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
    Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.